STK33
Serine/threonine kinase 33
Serine/Threonine Kinase 33 (STK33) plays a pivotal role in cancer cell proliferation and metastasis by phosphorylating serine and threonine residues on proteins, thereby regulating crucial cellular processes such as signal transduction, DNA replication, cell differentiation, proliferation, apoptosis, and tumor development. STK33 is overexpressed in various cancers, including pancreatic, lung, and liver cancers, compared to non-cancerous tissues. Notably, STK33 activates the PI3K/Akt/mTOR signaling pathway in gastric cancer, promoting metastasis. Additionally, the STK33/ERK2 signaling pathway contributes to the tumorigenesis of colorectal cancer by phosphorylating ERK2, enhancing its activity and promoting cancer progression. STK33's involvement in cancer development underscores its importance in oncology research.[1][2].
References:
- [1]. Jiang H, et al. Serine/Threonine Kinase (STK) 33 promotes the proliferation and metastasis of human esophageal squamous cell carcinoma via inflammation-related pathway. Pathol Res Pract. 2024 Feb;254:155154. [Content Brief]
- [2]. Zhang S, et al. STK33/ERK2 signal pathway contribute the tumorigenesis of colorectal cancer HCT15 cells. Biosci Rep. 2019 Mar 1;39(3):BSR20182351. [Content Brief]
All Product Categories
-
STK33 관련 제품 (8)
관련 제품 (8)
-
Antibodies (2)
-
ML281
0 ImagesML281 is a highly selective inhibitor of serine/threonine kinase 33 (STK33) with an IC50 value of 14 nM. ML281 shows 700-fold selectivity over PKA and 550-fold over AurB. ML281 exerts core mechanism by inhibiting STK33: in small cell lung cancer, ML281 downregulates RPS6/BAD signaling phosphorylation, induces apoptosis, and suppresses proliferation, invasion. ML281 reduces STK33-mediated 4-hydroxyphenylpyruvate dioxygenase (HPD) phosphorylation in tyrosinemia . ML281 is suitable for research on STK33 function, KRAS mutation-related cancers (pancreatic cancer, colon cancer, lung adenocarcinoma, etc.), small cell lung cancer, and tyrosinemia-related damage
-
CDD-2807
0 ImagesCDD-2807 is an inhibitor for serine/threonine kinase 33 (STK33) with IC50 of 9.2 nM. CDD-2807 exhibits no significant toxicity in mice and can cross the blood-testis barrier without accumulating in the brain. CDD-2807 induces a reversible contraceptive effect and has potential for the development of the male contraceptive.
-
DLK-IN-1
0 ImagesDLK-IN-1 (Compound 14) is an orally active, blood-brain barrier-penetrable and selective inhibitor of dual leucine zipper kinase (DLK, MAP3K12) with a Ki value of 3 nM. DLK-IN-1 inhibits Flt3, PAK4, STK33 and TrkA. DLK-IN-1 reduces p-c-Jun. DLK-IN-1 can be used in Alzheimer's disease research.
-
BRD-8899
0 ImagesCat. No.: HY-13498CAS No.: 1404437-50-8BRD-8899 is a STK33 inhibitor, with an IC50 of 11 nM.
-
CDD-2211
0 ImagesCat. No.: HY-176885CAS No.: 3086535-51-2
-
STK33-IN-1
0 ImagesCat. No.: HY-13497CAS No.: 1404437-49-5STK33-IN-1 (compound 1) is a STK33 inhibitor, with an IC50 of 7 nM.
-
CDD-2110
0 ImagesCat. No.: HY-176884CAS No.: 3086535-49-8
-
CDD-2212
0 ImagesCat. No.: HY-176885ACAS No.: 3086535-52-3
